This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

DARZALEX - MMY3008 (MAIA) study summary

DARZALEX® (daratumumab) received approval from the FDA on June 27, 2019 for the treatment of newly diagnosed multiple myeloma (NDMM) in combination with lenalidomide and dexamethasone (Rd) in adult patients who are ineligible for autologous stem cell transplant (ASCT) based on the MAIA trial.1,2


MAIA (NCT02252172) was a randomized, open-label, multicenter, active-controlled, phase 3 study evaluating the safety and efficacy of DARZALEX® in combination with Rd (DRd) vs Rd in patients with NDMM ineligible for ASCT.1,3

Key eligibility criteria3
  • Transplant-ineligible (TIE) NDMM
  • ECOG PS ≤2
  • CrCl ≥30 mL/min
Stratification factors3
  • ISS disease stage (I, II, or III)
  • Geographic region (North America vs other)
  • Age (<75 vs ≥75 years)

*On days when daratumumab was administered, dexamethasone was administered to patients in the DRd arm and served as the treatment dose of steroid for that day as well as the required pre-infusion medication.
†For patients older than 75 years of age or with BMI <18.5, dexamethasone was administered at a dose of 20 mg QW.

Primary endpoint1,3
  • Progression-free survival (PFS) based on International Myeloma Working Group (IMWG) criteria
Key secondary endpoints1,3
  • Complete response (CR) rate
  • Very good partial response (VGPR) rate
  • Overall survival (OS)
  • Overall response rate (ORR)
  • Minimal residual disease (MRD)-negativity rate (next-generation sequencing [NGS]: 10-5)
  • Safety

Baseline characteristics3*:

*The ITT population included all patients who underwent randomization. Post hoc analyses showed no significant differences between the two groups in the characteristics evaluated at baseline.
†ECOG PS is scored on a scale from 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability.
‡Two patients had a score of greater than 2 (one patient had a score of 3, and another patient had a score of 4).
§The ISS disease stage, which is derived on the basis of the combination of serum β2-microglobulin and albumin levels, consists of three stages. Higher stages indicate more severe disease.
‖This category includes IgD, IgE, IgM, and biclonal.
Cytogenetic risk was based on fluorescence in situ hybridization or karyotype analysis; patients who had a high-risk cytogenetic profile had at least one high-risk abnormality (del17p, t[14;16], or t[4;14]).

Primary endpoint: progression-free survival1

After 28 months of follow-up:

  • MAIA demonstrated an improvement in PFS in the DRd arm compared with the Rd arm; the median PFS had not been reached in the DRd arm and was 31.9 months (95% CI, 28.9–NR) in the Rd arm (HR, 0.56; 95% CI, 0.43–0.73; P<0.0001), representing a 44% reduction in the risk of disease progression or death in patients treated with DRd1,3
DRd3
(n =368)
Rd3
(n=369)
30-month estimated PFS rate, % (95% CI) 70.6 (65.0-75.4) 55.6 (49.5-61.3)
PD or death at 28 months, n (%) 97 (26.4) 143 (38.8)

After 64.5 months of follow-up:

  • Median PFS was 61.9 months (95% CI, 54.8–NE) in the DRd arm and 34.4 months (95% CI, 29.6-39.2) in the Rd arm1
DRd5 Rd5
60-month estimated PFS rate, % 52.1 29.6

After 56 months of follow-up:

  • A 32% reduction in the risk of death was observed with DRd vs Rd, and median OS had not been reached for either arm1
DRd6 Rd6
60-month estimated PFS rate, % (95% CI) 66.3 (60.8-71.3) 53.1 (47.2-58.6)

After 89 months of follow-up:

  • Median OS was 90.3 months (95% CI, 80.8–NE) in the DRd arm and 64.1 months (95% CI, 56.0-70.8) in the Rd arm1
DRd7 Rd7
7-year estimated OS rate, % (95% CI) 53.1 (47.8–58.2) 39.3 (34.1–44.5)

After 28 months of follow-up:

The following analysis is not included in the Prescribing Information for DARZALEX®. This analysis was not adjusted for multiple comparisons, and no conclusions should be drawn.

After 64.5 months of follow-up:

After 28 months of follow-up:

The following analysis is not included in the Prescribing Information for DARZALEX®. This analysis was not adjusted for multiple comparisons, and no conclusions should be drawn.

After 64.5 months of follow-up:

These analyses are not included in the Prescribing Information for DARZALEX®. These analyses were conducted post hoc, and there are insufficient numbers of patients per subgroup to make definitive conclusions of efficacy among the subgroups.

Objective: This post hoc subgroup analysis describes the efficacy and safety by baseline frailty in MAIA at a median follow-up of 64.5 months

Methods:

  • Frailty assessed using the IFM simplified frailty score at baseline
    • Non-frail = score of 0/1
    • Frail = score of ≥2

IFM simplified frailty index9

Score assessment Score
Age(years) ≤75 0
76–80 1
>80 2
CCI ≤1 0
>1 1
ECOG PS 0 0
1 1
≥2 2

Results:

Patient population

  • Overall, 737 patients included (DRd, n=368; Rd, n=369)
  • Median age of 73 years (range, 45-90)
  • A total of 341 (46%) patients were frail, 88.0% of whom were ≥70 years

Objective: Reports efficacy and safety data from age subgroups (<70 years, ≥70 to <75 years, and ≥80 years) with a median follow-up of 64.5 months

Results:

Demographic and baseline disease characteristics in the ITT population and by age subgroup13

  • A total of 737 patients (DRd, n=368; Rd, n=369) were randomized in MAIA. Baseline characteristics were well balanced between treatment arms5
Characteristic ITT <70 years ≥70 to <75 years ≥75 years ≥80 years
DRd
(n=368)
Rd
(n=369)
DRd
(n=78)
Rd
(n=77)
DRd
(n=130)
Rd
(n=131)
DRd
(n=160)
Rd
(n=161)
DRd
(n=66)
Rd
(n=71)
Median age,
years (range)
73 (50-90) 74 (45-89) 68 (50-69) 68 (45-69) 72 (70-74) 72 (70-74) 78 (75-90) 79 (75-89) 82 (79-90) 82 (80-89)
ECOG PS score, n (%)*
0 127 (34.5) 123 (33.3) 34 (43.6) 28 (36.4) 42 (32.3) 48 (36.6) 51 (31.9) 47 (29.2) 21 (31.8) 18 (25.4)
1 178 (48.4) 187 (50.7) 31 (39.7) 37 (48.1) 69 (53.1) 67 (51.1) 78 (48.8) 83 (51.6) 32 (48.5) 37 (52.1)
≥2 63 (17.1) 59 (16.0) 13 (16.7) 12 (15.6) 19 (14.6) 16 (12.2) 31 (19.4) 31 (19.3) 13 (19.7) 16 (22.5)
ISS disease stage, n (%)†
I 98 (26.6) 103 (27.9) 31 (39.7) 25 (32.5) 34 (26.2) 41 (31.3) 33 (20.6) 37 (23.0) 13 (19.7) 13 (18.3)
II 163 (44.3) 156 (42.3) 21 (26.9) 32 (41.6) 67 (51.5) 54 (41.2) 75 (46.9) 70 (43.5) 27 (40.9) 28 (39.4)
III 107 (29.1) 110 (29.8) 26 (33.3) 20 (26.0) 29 (22.3) 36 (27.5) 52 (32.5) 54 (33.5) 26 (39.4) 30 (42.3)
Type of measurable disease, n (%)
IgG 225 (61.1) 231 (62.6) 44 (56.4) 45 (58.4) 79 (60.8) 82 (62.6) 102 (63.8) 104 (64.6) 41 (62.1) 41 (57.7)
IgA 65 (17.7) 66 (17.9) 13 (16.7) 18 (23.4) 26 (20.0) 21 (16.0) 26 (16.3) 27 (16.8) 13 (19.7) 10 (14.1)
Other‡ 9 (2.4) 10 (2.7) 2 (2.6) 1 (1.3) 2 (1.5) 4 (3.1) 5 (3.1) 5 (3.1) 2 (3.0) 4 (5.6)
Detected in urine only 40 (10.9) 34 (9.2) 12 (15.4) 9 (11.7) 12 (9.2) 12 (9.2) 16 (10.0) 13 (8.1) 4 (6.1) 8 (11.3)
Detected in serum free light chains only 29 (7.9) 28 (7.6) 7 (9.0) 4 (5.2) 11 (8.5) 12 (9.2) 11 (6.9) 12 (7.5) 6 (9.1) 8 (11.3)
Cytogenetic profile,
n (%)§
(n=319) (n=323) (n=66) (n=66) (n=112) (n=119) (n=141) (n=138) (n=57) (n=60)
Standard risk 271 (85.0) 279 (86.4) 56 (84.8) 58 (87.9) 98 (87.5) 103 (86.6) 117 (83.0) 118 (85.5) 47 (82.5) 52 (86.7)
High risk 48 (15.0) 44 (13.6) 10 (15.2) 8 (12.1) 14 (12.5) 16 (13.4) 24 (17.0) 20 (14.5) 10 (17.5) 8 (13.3)
Median time since initial diagnosis of MM,
months (range)
0.95
(0.1-13.3)
0.89
(0-14.5)
0.85
(0.2-6.2)
0.82
(0.3-14.5)
0.90
(0.1-8.7)
0.95
(0.2-9.2)
0.95
(0.2-13.3)
0.92
(0.0-9.2)
1.02
(0.2-13.3)
0.95
(0.0-9.2)

*ECOG PS is scored on a scale of 0 to 5, with 0 indicating no symptoms and higher scores indicating increasing disability. †ISS disease stage was based on the combination of serum β2-microglobulin and albumin. ‡Includes IgD, IgM, IgE, and biclonal. §Cytogenetic risk was assessed by fluorescence in situ hybridization or karyotype testing; high risk was defined as the presence of t(4;14), t(14;16), or del(17p).

PFS with DRd and Rd for subgroups of patients aged <70 years, ≥70 to <75 years, and ≥75 years5

PFS with DRd and Rd for subgroups of patients aged >80 years5

Response rates by age subgroup in the ITT population5

MRD-negativity (10-5) rates by age subgroup in the ITT population5

After 28 months of follow-up:

  • Serious adverse reactions with a 2% greater incidence in the DRd arm compared to the Rd arm were1:
    • Pneumonia (DRd 15% vs Rd 8%)
    • Bronchitis (DRd 4% vs Rd 2%)
    • Dehydration (DRd 2% vs Rd <1%)

Adverse reactions reported in ≥10% of patients and with at least a 5% greater frequency in the DRd arm in MAIA1

Adverse reaction DRd
(n=364)
Rd
(n=365)
All grades
(%)
Grade 3
(%)
Grade 4
(%)
All grades
(%)
Grade 3
(%)
Grade 4
(%)
Gastrointestinal disorders
Diarrhea 57 7 0 46 4 0
Constipation 41 1 <1 36 <1 0
Nausea 32 1 0 23 1 0
Vomiting 17 1 0 12 <1 0
Infections
Upper respiratory tract infection* 52 2 <1 36 2 <1
Bronchitis† 29 3 0 21 1 0
Pneumonia‡ 26 14 1 14 7 1
Urinary tract infection 18 2 0 10 2 0
General disorders and administration site conditions
Infusion-related reactions§ 41 2 <1 0 0 0
Peripheral edema‖ 41 2 0 33 1 0
Fatigue 40 8 0 28 4 0
Asthenia 32 4 0 25 3 <1
Pyrexia 23 2 0 18 2 0
Chills 13 0 0 2 0 0
Musculoskeletal and connective tissue disorders
Back pain 34 3 <1 26 3 <1
Muscle spasms 29 1 0 22 1 0
Respiratory, thoracic and mediastinal disorders
Dyspnea 32 3 <1 20 1 0
Cough# 30 <1 0 18 0 0
Nervous system disorders
Peripheral sensory neuropathy 24 1 0 15 0 0
Headache 19 1 0 11 0 0
Paresthesia 16 0 0 8 0 0
Metabolism and nutrition disorders
Decreased appetite 22 1 0 15 <1 <1
Hyperglycemia 14 6 1 8 3 1
Hypocalcemia 14 1 <1 9 1 1
Vascular disorders
Hypertension** 13 6 <1 7 4 0

*Acute sinusitis, bacterial rhinitis, laryngitis, metapneumovirus infection, nasopharyngitis, oropharyngeal candidiasis, pharyngitis, respiratory syncytial virus infection, respiratory tract infection, respiratory tract infection viral, rhinitis, rhinovirus infection, sinusitis, tonsillitis, tracheitis, upper respiratory tract infection, viral pharyngitis, viral rhinitis, viral upper respiratory tract infection.
†Bronchiolitis, bronchitis, bronchitis viral, respiratory syncytial virus bronchiolitis, tracheobronchitis.
‡Atypical pneumonia, bronchopulmonary aspergillosis, lung infection, Pneumocystis jirovecii infection, Pneumocystis jirovecii pneumonia, pneumonia, pneumonia aspiration, pneumonia pneumococcal, pneumonia viral, pulmonary mycosis.
§Infusion-related reaction includes terms determined by investigators to be related to infusion.
‖Generalized edema, gravitational edema, edema, peripheral edema, peripheral swelling.
Dyspnea, dyspnea exertional.
#Cough, productive cough.
**Blood pressure increased, hypertension.

DRd
(n=364)
Rd
(n=365)
All grades
(%)
Grade 3
(%)
Grade 4
(%)
All grades
(%)
Grade 3
(%)
Grade 4
(%)
Leukopenia 90 30 5 82 20 4
Neutropenia 91 39 17 77 28 11
Lymphopenia 84 41 11 75 36 6
Thrombocytopenia 67 6 3 58 7 4
Anemia 47 13 0 57 24 0

This analysis is not included in the Prescribing Information. This analysis was not adjusted for multiple comparisons, and no conclusions should be drawn.

Summary of any grade (≥30%) and Grade 3/4 (≥20%) TEAEs in the safety population5

DRd
(n=364)
Rd
(n=365)
Any grade Grade 3/4 Any grade Grade 3/4
Hematologic, n (%)
Neutropenia 224 (61.5) 197 (54.1) 166 (45.5) 135 (37.0)
Anemia 154 (42.3) 62(17.0) 150 (41.1) 79 (21.6)
Non-hematologic, n (%)
Diarrhea 240 (65.9) 33 (9.1) 188 (51.5) 22 (6.0)
Fatigue 164 (45.1) 33 (9.1) 114 (31.2) 17 (4.7)
Constipation 157 (43.1) 6 (1.6) 137 (37.5) 2 (0.5)
Peripheral edema 155 (42.6) 10 (2.7) 117 (32.1) 3 (0.8)
Back pain 155 (42.6) 14 (3.8) 109 (29.9) 14 (3.8)
Asthenia 136 (37.4) 19 (5.2) 101 (27.7) 18 (4.9)
Nausea 133 (36.5) 7 (1.9) 88 (24.1) 2 (0.5)
Insomnia 125 (34.3) 11 (3.0) 116 (31.8) 14 (3.8)
Bronchitis 124 (34.1) 12 (3.3) 87 (23.8) 7 (1.9)
Pneumonia 113 (31.0) 71 (19.5) 66 (18.1) 39 (10.7)
Cough 123 (33.8) 2 (0.5) 65 (17.8) 0
Dyspnea 119 (32.7) 12 (3.3) 63 (17.3) 4 (1.1)
Weight decreased 112 (30.8) 10 (2.7) 69 (18.9) 11 (3.0)
Muscle spasms 111 (30.5) 2 (0.5) 86 (23.6) 5 (1.4)
Peripheral sensory neuropathy 111 (30.5) 9 (2.5) 66 (18.1) 2 (0.5)

This analysis is not included in the Prescribing Information. This analysis was not adjusted for multiple comparisons, and no conclusions should be drawn.

Summary of death and causes of death in the safety population11*

n (%) DRd
(n=364)
Rd
(n=365)
Total number of patients who died during the study 173 (47.5) 218 (59.7)
Primary cause of death
Disease progression 76 (20.9) 88 (24.1)
AEs 44 (12.1) 40 (11.0)
Related to study treatment† 14 (3.8) 10 (2.7)
Unrelated to study treatment 28 (7.7) 29 (7.9)
Other ‡ 53 (14.6) 90 (24.7)
Infections/infestations 9 (2.5) 30 (8.2)
General disorders/administration site conditions§ 11 (3.0) 5 (1.4)
Neoplasms (benign, malignant, or unspecified) 11 (3.0) 4 (1.1)
Cardiac disorders 1 (0.3) 8 (2.2)
Nervous system disorders 3 (0.8) 5 (1.4)
Unknown 13 (3.6) 27 (7.4)
Deaths within 30 days of last study treatment dose 31 (8.5) 35 (9.6)
Primary cause of death
Disease progression 1 (0.3) 1 (0.3)
AEs 29 (8.0) 32 (8.8)
Related to study treatment† 11 (3.0) 10 (2.7)
Unrelated to study treatment 18 (4.9) 22 (6.0)
Other‖ 1 (0.3) 2 (0.5)

*The safety population included all randomized patients who received ≥1 dose of study treatment.
†AEs were related to ≥1 of the 3 components of study treatment: daratumumab, lenalidomide, and dexamethasone.
‡Other reasons were reported in ≥1% of patients in either treatment group.
§All events were related to the general health condition of the patient.
‖Includes a nervous system disorder in 1 patient in the DRd group and a blood and lymphatic system disorder and general disorder/administration site condition in 1 patient each in the Rd group.

These analyses are not included in the Prescribing Information for DARZALEX®. These analyses were conducted post hoc, and there are insufficient numbers of patients per subgroup to make definitive conclusions of safety among the subgroups.

After 64.5 months of follow-up:

  • Rates of Grade 3/4 TEAEs were generally higher in frail vs non-frail patients
  • COVID-19 infections/pneumonia were reported in <2% of patients in the DRd arm across subgroups
  • There were no new safety signals beyond the typical neutropenia and infection TEAEs occurring with DRd
  • The incidence of TEAEs leading to study treatment discontinuation was slightly lower in the DRd arm across frailty subgroups
  • The incidence of related serious TEAEs was similar in those receiving DRd compared with Rd across most frailty subgroups

Grade 3/4 TEAEs and treatment-related discontinuations

n (%) Non-frail Frail
DRd
(n=196)
Rd
(n=199)
DRd
(n=168)
Rd
(n=166)
Any Grade 3/4 TEAE 188 (95.9) 172 (86.4) 161 (95.8) 152 (91.6)
Neutropenia 96 (49.0) 79 (39.7) 101 (60.1) 56 (33.7)
Infections & infestations SOC 77 (39.3) 55 (27.6) 78 (46.4) 53 (31.9)
TEAE leading to study treatment discontinuation 26 (13.3) 47 (23.6) 27 (16.1) 40 (24.1)

Causes of death

n (%) Non-frail Frail
DRd
(n=196)
Rd
(n=199)
DRd
(n=168)
Rd
(n=166)
TEAE 7 (3.6) 10 (5.0) 22 (13.1) 21 (12.7)
Progressive disease 26 (13.3) 40 (20.1) 30 (17.9) 29 (17.5)

After 64.5 months of follow-up:

  • Grade 3/4 TEAEs occurred in 95.5% of patients in the DRd arm vs 95.0% in the Rd arm who were ≥75 years of age and 92.3% and 95.7%, respectively, in those ≥80 years of age

Safety profile in patients ≥75 years of age

  • Serious TEAEs occurred in 80.9% of patients in the DRd arm and 79.2% in the Rd arm, with pneumonia being the most common (19.7% and 12.6%, respectively)
  • TEAEs that led to treatment discontinuation occurred in 15.3% of patients in the DRd arm and 27.7% in the Rd arm
  • TEAEs with an outcome of death occurred in 11.5% of patients in the DRd arm and 13.2% in the Rd arm

Safety profile in patients ≥80 years of age

  • Serious TEAEs occurred in 81.5% of patients in the DRd arm and 82.9% in the Rd arm, with pneumonia being the most common (24.6% and 8.6%, respectively)
  • TEAEs that led to treatment discontinuation occurred in 6.2% of patients in the DRd arm and 20.0% in the Rd arm
  • TEAEs with an outcome of death occurred in 12.3% of patients in the DRd arm and 11.4% in the Rd arm

Most common any grade or Grade 3/4 TEAEs among patients aged ≥75 years and ≥80 years in the safety population10*

TEAE, n(%) ≥75 years ≥80 years
DRd (n=157) Rd (n=159) DRd (n=65) Rd (n=70)
Any grade Grade 3/4 Any grade Grade 3/4 Any grade Grade 3/4 Any grade Grade 3/4
Hematologic
Neutropenia 109 (69.4) 98 (62.4) 81 (50.9) 66 (41.5) 45 (69.2) 37 (56.9) 34 (48.6) 26 (37.1)
Anemia 71 (45.2) 32 (20.4) 73 (45.9) 40 (25.2) 31 (47.7) 12 (18.5) 35 (50.0) 19 (27.1)
Thrombocytopenia 39 (24.8) 16 (10.2) 43 (27.0) 19 (11.9) 21 (32.3) 7 (10.8) 20 (28.6) 8 (11.4)
Lymphopenia 37 (23.6) 33 (21.0) 25 (15.7) 20 (12.6) 10 (15.4) 8 (12.3) 13 (18.6) 10 (14.3)
Non-hematologic
Diarrhea 98 (62.4) 16 (10.2) 80 (50.3) 8 (5.0) 37 (56.9) 5 (7.7) 35 (50.0) 3 (4.3)
Peripheral edema 76 (48.4) 6 (3.8) 53 (33.3) 2 (1.3) 31 (47.7) 0 24 (34.3) 2 (2.9)
Constipation 75 (47.8) 2 (1.3) 61 (38.4) 1 (0.6) 27 (41.5) 0 27 (38.6) 1 (1.4)
Fatigue 73 (46.5) 15 (9.6) 48 (30.2) 8 (5.0) 26 (40.0) 7 (10.8) 19 (27.1) 3 (4.3)
Back pain 65 (41.4) 7 (4.5) 53 (33.3) 6 (3.8) 24 (36.9) 2 (3.1) 21 (30.0) 2 (2.9)
Asthenia 58 (36.9) 8 (5.1) 43 (27.0) 10 (6.3) 25 (38.5) 3 (4.6) 26 (37.1) 8 (11.4)
Weight decreased 49 (31.2) 6 (3.8) 31 (19.5) 5 (3.1) 19 (29.2) 2 (3.1) 16 (22.9) 2 (2.9)
Bronchitis 48 (30.6) 7 (4.5) 31 (19.5) 4 (2.5) 18 (27.7) 2 (3.1) 15 (21.4) 1 (1.4)
Nausea 48 (30.6) 2 (1.3) 40 (25.2) 0 21 (32.3) 1 (1.5) 20 (28.6) 0
Pneumonia 44 (28.0) 32 (20.4) 33 (20.8) 23 (14.5) 22 (33.8) 17 (26.2) 13 (18.6) 8 (11.4)
Pyrexia 44 (28.0) 6 (3.8) 22 (13.8) 3 (1.9) 20 (30.8) 4 (6.2) 7 (10.0) 0

*Any grade TEAEs and Grade 3/4 TEAEs listed are those that occurred in ≥30% and ≥20% of patients in either group, respectively.

Contraindications1:

DARZALEX® is contraindicated in patients with a history of severe hypersensitivity (e.g. anaphylactic reactions) to daratumumab or any of the components of the formulation.

Warnings and precautions1:

Please see the full prescribing information for more details.

Infusion-related reactions
  • DARZALEX® can cause severe and/or serious infusion-related reactions including anaphylactic reactions
  • These reactions can be life-threatening, and fatal outcomes have been reported
  • In clinical trials (monotherapy and combination: N=2,066), infusion-related reactions occurred in 37% of patients with the Week 1 (16 mg/kg) infusion, 2% with the Week 2 infusion, and cumulatively 6% with subsequent infusions
  • Less than 1% of patients had a Grade 3/4 infusion-related reaction at Week 2 or subsequent infusions
  • The median time to onset was 1.5 hours (range: 0 to 73 hours)
  • Nearly all reactions occurred during infusion or within 4 hours of completing DARZALEX®
  • Severe reactions have occurred, including bronchospasm, hypoxia, dyspnea, hypertension, tachycardia, headache, laryngeal edema, pulmonary edema, and ocular adverse reactions, including choroidal effusion, acute myopia, and acute angle closure glaucoma
  • Signs and symptoms may include respiratory symptoms, such as nasal congestion, cough, throat irritation, as well as chills, vomiting and nausea. Less common signs and symptoms were wheezing, allergic rhinitis, pyrexia, chest discomfort, pruritus, hypotension, and blurred vision
  • When DARZALEX® dosing was interrupted in the setting of ASCT (CASSIOPEIA) for a median of 3.75 months (range: 2.4 to 6.9 months), upon re-initiation of DARZALEX®, the incidence of infusion-related reactions was 11% for the first infusion following ASCT
  • Infusion rate/dilution volume used upon re-initiation was that used for the last DARZALEX® infusion prior to interruption for ASCT. Infusion-related reactions occurring at re-initiation of DARZALEX® following ASCT were consistent in terms of symptoms and severity (Grade 3 or 4: <1%) with those reported in previous studies at Week 2 or subsequent infusions
  • In EQUUELUS, patients receiving combination treatment (n=97) were administered the first 16 mg/kg dose at Week 1 split over two days i.e. 8 mg/kg on Day 1 and Day 2, respectively
  • The incidence of any grade infusion-related reactions was 42%, with 36% of patients experiencing infusion-related reactions on Day 1 of Week 1, 4% on Day 2 of Week 1, and 8% with subsequent infusions
  • Pre-medicate patients with antihistamines, antipyretics and corticosteroids
  • Frequently monitor patients during the entire infusion
  • Interrupt DARZALEX® infusion for reactions of any severity and institute medical management as needed
  • Permanently discontinue DARZALEX® therapy if an anaphylactic reaction or life-threatening (Grade 4) reaction occurs and institute appropriate emergency care
  • For patients with Grade 1, 2, or 3 reactions, reduce the infusion rate when re-starting the infusion
  • To reduce the risk of delayed infusion-related reactions, administer oral corticosteroids to all patients following DARZALEX® infusions
  • Patients with a history of chronic obstructive pulmonary disease may require additional post-infusion medications to manage respiratory complications
  • Consider prescribing short- and long-acting bronchodilators and inhaled corticosteroids for patients with chronic obstructive pulmonary disease
  • Ocular adverse reactions, including acute myopia and narrowing of the anterior chamber angle due to ciliochoroidal effusions with potential for increased intraocular pressure or glaucoma, have occurred with DARZALEX® infusion
  • If ocular symptoms occur, interrupt DARZALEX® infusion and seek immediate ophthalmologic evaluation prior to restarting DARZALEX®
Infections
  • DARZALEX® can cause serious, life-threatening, or fatal infections. In patients who received DARZALEX® in a pooled safety population (N=2066), serious infections, including opportunistic infections, occurred in 22.6% of patients, Grade 3 or 4 infections occurred in 24.3%, and fatal infections occurred in 1.2%
  • The most common (≥2%) types of serious infection reported were pneumonia (11%), upper respiratory tract infection (4%), sepsis (3%), and bronchitis (2%)
  • Monitor patients for signs and symptoms of infection prior to and during treatment with DARZALEX® and treat appropriately. Administer prophylactic antimicrobials according to guidelines
Interference with serological testing
  • Daratumumab binds to CD38 on RBCs and results in a positive Indirect Antiglobulin Test (Indirect Coombs test)
  • Daratumumab-mediated positive indirect antiglobulin test may persist for up to 6 months after the last daratumumab infusion
  • Daratumumab bound to RBCs masks detection of antibodies to minor antigens in the patient’s serum
  • The determination of a patient’s ABO and Rh blood type are not impacted
  • Notify blood transfusion centers of this interference with serological testing and inform blood banks that a patient has received DARZALEX®
  • Type and screen patients prior to starting DARZALEX®
Neutropenia and thrombocytopenia
  • DARZALEX® may increase neutropenia and thrombocytopenia induced by background therapy
  • Monitor complete blood cell counts periodically during treatment according to manufacturer’s prescribing information for background therapies
  • Monitor patients with neutropenia for signs of infection
  • Consider withholding DARZALEX® until recovery of neutrophils or for recovery of platelets
Interference with determination of complete response
  • Daratumumab is a human IgG kappa monoclonal antibody that can be detected on both, the serum protein electrophoresis and immunofixation assays used for the clinical monitoring of endogenous M‑protein
  • This interference can impact the determination of complete response and of disease progression in some patients with IgG kappa myeloma protein
Embryo-fetal toxicity
  • Based on the mechanism of action, DARZALEX® can cause fetal harm when administered to a pregnant woman
  • DARZALEX® may cause depletion of fetal immune cells and decreased bone density
  • Advise pregnant women of the potential risk to a fetus
  • Advise females with reproductive potential to use effective contraception during treatment with DARZALEX® and for 3 months after the last dose
  • The combination of DARZALEX® with lenalidomide, pomalidomide, or thalidomide is contraindicated in pregnant women, because lenalidomide, pomalidomide, and thalidomide may cause birth defects and death of the unborn child
  • Refer to the lenalidomide, pomalidomide, or thalidomide Prescribing Information on use during pregnancy
Adverse reactions
  • The most frequently reported adverse reactions (incidence ≥20%) were upper respiratory infection, neutropenia, infusion-related reactions, thrombocytopenia, diarrhea, constipation, anemia, peripheral sensory neuropathy, fatigue, peripheral edema, nausea, cough, pyrexia, dyspnea, and asthenia
  • The most common hematologic laboratory abnormalities (≥40%) with DARZALEX® are neutropenia, lymphopenia, thrombocytopenia, leukopenia, and anemia
  1. DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. U.S. FDA approves DARZALEX® (daratumumab) for multiple myeloma ineligible for autologous stem cell transplant. News release. Janssen Biotech, Inc.; June 27, 2019. Accessed May 1, 2026. https://wayback.archive-it.org/7993/20201222063947/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-multiple-myeloma-ineligible-autologous-stem-cell-transplant
  3. Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115.
  4. Supplement to: Facon T, Kumar S, Plesner T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104-2115.
  5. Facon T, Moreau P, Weisel K, et al. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39(4):942-950.
  6. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582-1596.
  7. Facon T, Kumar SK, Orlowski RZ, et al. Daratumumab, lenalidomide, and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: MAIA final survival analysis. Leukemia. 2026. doi:10.1038/s41375-026-03097-9.
  8. Venner CP, Zweegman S, Kumar SK, et al. Age and frailty analyses of transplant-ineligible patients with newly diagnosed multiple myeloma in the phase 3 MAIA and CEPHEUS trails of daratumumab + lenalidomide-dexamethasone and bortezomib + lenalidomide-dexamethasone. Poster presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; May 29-June 2, 2026; Chicago, IL.
  9. Larocca A, Marenchino D, Varettoni M, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224-233.
  10. Facon T, Moreau P, Weisel K, et al. Daratumumab/lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma: MAIA long-term outcomes. Leukemia. 2025;39(4):942-950 [supplementary appendix].
  11. Facon T, Kumar SK, Orlowski R, et al. Final survival analysis of daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: MAIA study. Poster presented at: The European Hematology Association (EHA) Hybrid Congress; June 13-16, 2024; Madrid, Spain.
ABO ABO blood group system NDMM Newly diagnosed multiple myeloma
AE Adverse event NE Not estimable
ASCT Autologous stem cell transplant NGS Next-generation sequencing
BMI Body mass index NR Not reached
CCI Charlson comorbidity index OR Odds ratio
CD38 Cluster of differentiation 38 ORR Overall response rate
CI Confidence interval OS Overall survival
COVID-19 Coronavirus disease 2019 PD Progressive disease
CR Complete response PFS Progression-free survival
CrCl Creatinine clearance PO Oral
D Daratumumab PR Partial response
d Dexamethasone Q2W Every 2 weeks
DRd Daratumumab + lenalidomide + dexamethasone Q4W Every 4 weeks
ECOG PS Eastern Cooperative Oncology Group performance status QW Weekly
FDA U.S. Food and Drug Administration R Lenalidomide
HR Hazard ratio RBC Red blood cell
IFM Intergroupe Francophone du Myélome Rd Lenalidomide + dexamethasone
Ig Immunoglobulin Rh Rh blood group system
IMWG International Myeloma Working Group sCR Stringent complete response
ISS International Staging System SOC System organ class
ITT Intention-to-treat TEAE Treatment-emergent adverse event
IV Intravenous TIE Transplant ineligible
MM Multiple myeloma VGPR Very good partial response
MRD Minimal residual disease
J&J Medical Connect

Connect with us

  • Products

Would you like to clear and leave your conversation? Message history will be lost.